Here is what I had in my notes from the april 27th

New Post Public Reply Private Reply Replies (0) Message Board
z_smith01 ClosetInvestor #37178
854
Here is what I had in my notes from the april 27th call.

Q: In our Feb 6th conference call you stated that Dr. Kelly had identified a company to do a pre-clinical study more analogous to the studies forming the basis of material licensing deals in NASH. Could you provide an update on that pre-clinical work?
A: It is going forward. It will be a few more weeks before they can announce the start of that pre-clinical study.

And from the May 26th call:
Q: NASH
A: Scott K. hired company to do special animal study. Results could lead to a licensing agreement.
P2 NASH could start.
Probably want to start this trial.
Plan: Uplist, hit primary endpoint on COVID, then start all the indications.

+++++

And here is some background research on NASH deals

NASH licensing deals

It causes fatty build-up and fibrosis in the liver, sometimes leading to cirrhosis and the need for a liver transplant, and so far has no approved treatments with some analysts predicting the market for NASH drugs could go from a standing start to more than $20bn in just a few years.

+++++++

Allergen
It subsequently made a bold entry into the non-alcoholic steatohepatitis
(NASH) market with the complementary acquisitions of US-based Tobira Therapeutics
(Deal no. 73620) and UK-based Akarna Therapeutics (Deal no. 73633). The key driver of
the Tobira deal, which is potentially worth up to US$1.7 B was the Phase III-ready asset
cenicriviroc, an immunomodulator and dual inhibitor of the CCR2 and CCR5 chemokine
receptors.


++++++
Novartis in nearly $1.6B deal to buy NASH-focused subsidiary of IFM Therapeutics
The deal includes a $310 million upfront payment plus milestones for three IFM Tre assets - one clinical drug for NASH and atherosclerosis and two preclinical molecules.

++++++
Investors in Ionis Pharmaceuticals are happy this morning after the California-based company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.

++++++

Yuhan will receive an upfront payment of $40 million, of which $10 million comes after a preclinical toxicity test. The company will also get the other $830 million in potential milestone payments upon achievement of drug development, approval, and sales. If the drug is commercialized, the company will receive additional royalties depending on net sales.

++++++

NGM Bio and Merck started working together in 2015, when the big pharma signed a $450m development deal with the biotech, including $200m in upfront fees and equity investment, to tap into its biologic drug discovery expertise. The lead NASH candidate at that time was NP 201, but seems to have been leapfrogged by NGM313, now renamed MK-3655.

Merck us paying $20m upfront for rights to NGM313 and follow-up compounds, with the deal following a phase 1b trial readout which showed that the antibody was able to reduce levels of fat in the liver and improve metabolic measures such as blood glucose control in obese NASH patients.

+++++

Under the terms of the licensing agreement, GENFIT will receive an upfront payment from Terns of $35 million and will be eligible to receive up to $193 million in potential clinical, regulatory and commercial milestone payments. Terns obtains the exclusive rights to develop, register and market elafibranor in mainland China, Hong Kong, Macau and Taiwan (“Greater China”) for both NASH and PBC. Upon commercial launch of elafibranor for the treatment of NASH in Greater China, GENFIT will be entitled to receive mid-teen percentage royalties from Terns based on sales in the territory.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 13

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 33

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 19

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 10

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading
Chargeback AI Still Has a Costly Last-Mile Problem

Updated Category News Views 41

A corrected headline is a small wrinkle, but the underlying chargeback mess is not. Chargeflow and Juniper Research surveyed 121 senior executives at U.S. and U.K. businesses with at least $100 million in annual gross merchandise value, and the useful takeaway is painfully clear: merchants are putting AI on the label without rebuilding the machinery underneath. That...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 31

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 50

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 67

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 42

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading

Top 5 Most Recently Viewed Articles

MAGNA-TILES Unveils Exciting Rail Racers To Transform Play

Updated Category News Views 562

MAGNA-TILES Innovates Play with Rail Racers Launch First Fan-Made Invention Reimagines Ball Runs and Takes Magnetic Building to the Next Level MAGNA-TILES, America’s favorite magnetic building toy brand, has introduced an exciting innovation—the Rail Racers. This remarkable new product debuted at the American International Toy Fair, showcasing the creativity of the...

Continue Reading
Discover DDB Miner’s Innovative Approach to Bitcoin Mining

Updated Category News Views 167

Unlocking the Future of Bitcoin Mining DDB Miner, a forward-thinking Bitcoin mining entity, is making significant strides in the cryptocurrency industry. By emphasizing low-cost and efficient operations, DDB Miner is set on a path to redefine how Bitcoin is mined. Their latest operational update sheds light on impressive developments and ambitious plans that promise to...

Continue Reading
Warren Buffett Plans Charitable Giving with New CEO Transition

Updated Category News Views 217

Warren Buffett Speeds Up Charitable Contributions Warren Buffett recently announced that he will accelerate the distribution of his vast fortune, amounting to $149 billion, to his children's charitable foundations. This strategic decision aligns with the responsibilities he feels as a father, recognizing the increasing ages of his children. The Transition to Greg Abel As...

Continue Reading
Understanding the DeFi Technologies Class Action and Its Impact

Updated Category News Views 238

DeFi Technologies Class Action Explained Robbins LLP recently brought to light a class action lawsuit on behalf of investors who bought or acquired shares of DeFi Technologies Inc. (NASDAQ: DEFT). This action covers a specific timeframe, reflecting concerns over the company’s alleged misrepresentation of its business prospects. Investors seeking clarity on this...

Continue Reading
Alibaba's Robotics Innovation: Shaping the Future of AI Tech

Updated Category News Views 199

Alibaba's Bold Move into Robotics Alibaba Group (NYSE: BABA) has embarked on an exciting new venture by launching its own robotics team to compete in the rapidly advancing field of AI-powered physical products. This initiative reflects Alibaba's commitment to integrating artificial intelligence into everyday applications, transforming how technology interacts with the...

Continue Reading